Estrella Immunopharma, Inc. (ESLAW) stock
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.09+0.02 (+25.07%)
Close on Nov 13, 2026Market cap $22.36MP/E –Yield –
Estrella Immunopharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Estrella Immunopharma's EPS for the twelve months ending Jun 30, 2024 was -$0.27. For fiscal 2024 it was -$0.27.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -$0.27 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ3 2025 | Jun 30, 2026 | -$0.11 | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$0.11 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$0.01 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$0.03 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$1.78 | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$0.10 | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$0.99 | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $0.00 | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?